| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
G-TPP manufacturers
- G-TPP
-
- $2.00
-
2026-08-25
- CAS:1131626-46-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| Product Name: | G-TPP | | Synonyms: | G-TPP;Gamitrinib TPP;Gamitrinib;17-Demethoxy-17-[[6-(triphenylphosphonio)hexyl]amino]geldanamycin (ACI) | | CAS: | 1131626-46-4 | | MF: | C52H65N3O8P+ | | MW: | 891.08 | | EINECS: | | | Product Categories: | | | Mol File: | 1131626-46-4.mol |  |
| | G-TPP Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | G-TPP Usage And Synthesis |
| Uses | Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity. | | in vivo | Interestingly, 2 cycles of intracranial TRAIL combined with systemic G-TPP suppress the growth of established glioblastomas, with no significant animal weight loss throughout treatment. Analysis of brain sections from these mice, but not single agent-treated animals, show loss of tumor cell proliferation, internucleosomal DNA fragmentation, and caspase-3 activity, consistent with extensive activation of apoptosis in vivo[1]. | | IC 50 | HSP90 | | References | [1] Markus D. Siegelin, et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011 Apr 1; 121(4): 1349–1360. DOI:10.1172/JCI44855 |
| | G-TPP Preparation Products And Raw materials |
|